Gam-COVID-Vac Lyo
Gam-COVID-Vac Lyo Uses, Dosage, Side Effects, Food Interaction and all others data.
Gam-COVID-Vac Lyo was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector which both carry the SARS-CoV-2 spike glycoprotein. The vaccine is offered in both a frozen (Gam-COVID-Vac Lyo) and freeze-dried formulation (lyophilizate; Gam-COVID-Vac Lyo Lyo). Phase 1/2 human trials with 76 participants evaluated the safety, tolerability, and immunogenicity of both frozen (Gam-COVID-Vac Lyo;NCT04436471) and freeze-dried (Gam-COVID-Vac Lyo Lyo;NCT04437875) vaccine candidates in June 2020, and were completed in early August 2020. Preliminary results suggested that all participants developed antibodies to the SARS-CoV-2 glycoproteins with a good safety profile in both trials.
| Trade Name | Gam-COVID-Vac Lyo |
| Generic | Gam-COVID-Vac |
| Gam-COVID-Vac Other Names | Gam-COVID-Vac Lyo, Sputnik V |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Gam-COVID-Vac Lyo
